Wolfe Research Upgrades Century Aluminum to Peer Perform
Wolfe Research analyst Timna Tanners upgrades Century Aluminum (NASDAQ:CENX) from Underperform to Peer Perform.
Why This Intel Analyst Is No Longer Bearish: ‘Paying A Dividend … Is Counterproductive’
Shares of Intel Corporation (NASDAQ: INTC) recovered lightly on Thursday morning, putting a temporary pause to its losing streak.
B of A Securities Upgrades TPI Composites to Buy, Raises Price Target to $14
B of A Securities analyst Julien Dumoulin-Smith upgrades TPI Composites (NASDAQ:TPIC) from Underperform to Buy and raises the price target from $9 to $14.
Deutsche Bank Upgrades Dun & Bradstreet Hldgs to Buy, Raises Price Target to $17
Deutsche Bank analyst Faiza Alwy upgrades Dun & Bradstreet Hldgs (NYSE:DNB) from Hold to Buy and raises the price target from $15 to $17.
Wolfe Research Upgrades Roper Technologies to Outperform, Announces $480 Price Target
Wolfe Research analyst Nigel Coe upgrades Roper Technologies (NYSE:ROP) from Peer Perform to Outperform and announces $480 price target.
Morgan Stanley Upgrades Intel to Equal-Weight, Lowers Price Target to $28
Morgan Stanley analyst Joseph Moore upgrades Intel (NASDAQ:INTC) from Underweight to Equal-Weight and lowers the price target from $29.5 to $28.
Credit Suisse Upgrades Cinemark Hldgs to Neutral, Raises Price Target to $12
Credit Suisse analyst Douglas Mitchelson upgrades Cinemark Hldgs (NYSE:CNK) from Underperform to Neutral and raises the price target from $9 to $12.
Piper Sandler Upgrades Wix.com to Neutral, Raises Price Target to $99
Piper Sandler analyst Clarke Jeffries upgrades Wix.com (NASDAQ:WIX) from Underweight to Neutral and raises the price target from $80 to $99.
Analyst Says This MedTech Giant Stock Offers ‘Too Much Optionality,’ Upgrades Rating
Raymond James upgraded Masimo Corporation (NASDAQ:MASI) from Market Perform To Outperform with a price target of $187 and says that no other company…
Analyst Sees Attractive Entry Opportunity After BioCryst’s Pipeline Setback
Tucked in its Q4 earnings press release, BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported a setback on the early-stage BCX10013 study. The company…